LD 254
pg. 3
Page 2 of 4 PUBLIC Law Chapter 430 Page 4 of 4
Download Chapter Text
LR 72
Item 1

 
(3)__All expenses associated with trips and travel; and

 
(4)__All expenses associated with product samples,
except for samples that will be distributed free of
charge to patients; and

 
C.__The aggregate cost of all employees or contractors of
the manufacturer or labeler who directly or indirectly
engage in the advertising or promotional activities listed
in paragraphs A and B, including all forms of payment to
those employees.__The cost reported under this paragraph
must reflect only that portion of payment to employees or
contractors that pertains to activities within this State or
to recipients of the advertising or promotional activities
who are residents of or are employed in this State.

 
5.__Exceptions.__The following marketing expenses are not
subject to the requirements of this section:

 
A.__Expenses of $25 or less;

 
B.__Reasonable compensation and reimbursement for expenses
in connection with a bona fide clinical trial of a new
vaccine, therapy or treatment; and

 
C.__Scholarships and reimbursement of expenses for attending
a significant educational, scientific or policy-making
conference or seminar of a national, regional or specialty
medical or other professional association if the recipient
of the scholarship is chosen by the association sponsoring
the conference or seminar.

 
6.__Department reports.__By November 30th each year, the
department shall provide an annual report, providing information
in aggregate form, on prescription drug marketing expenses to the
Legislature and the Attorney General.__By January 1, 2005 and
every 2 years after that date, the department shall provide a
report to the Legislature and the Attorney General, providing
information in aggregate form, containing an analysis of the data
submitted to the department, including the scope of prescription
drug marketing activities and expenses and their effect on the
cost, utilization and delivery of health care services and any
recommendations with regard to marketing activities of
prescription drug manufacturers and labelers.

 
7.__Confidentiality; public information.__Notwithstanding any
provision of law to the contrary, information submitted to the
department pursuant to this section is confidential and is not a
public record as defined in Title 1, section 402,


Page 2 of 4 Top of Page Page 4 of 4
Related Pages
  Search Bill Text Legislative Information
Bill Directory Search
Bill
Status
Session Information
119th Legislature Bills Maine Legislature

Office of Legislative Information
100 State House Station
Augusta, ME 04333
voice: (207) 287-1692
fax: (207) 287-1580
tty: (207) 287-6826
Word Viewer for Windows Disclaimer